Know Cancer

or
forgot password


Phase 3
5 Years
71 Years
Open (Enrolling)
Both
Li Fraumeni Syndrome

Thank you

Trial Information


Inclusion Criteria:



- P53 mutation

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

cancer incidence

Outcome Description:

cancer incidence during the first 3 years

Outcome Time Frame:

3 years

Safety Issue:

No

Authority:

France:AFSSAPS

Study ID:

CSET2011/1748

NCT ID:

NCT01464086

Start Date:

September 2011

Completion Date:

October 2016

Related Keywords:

  • Li Fraumeni Syndrome
  • patients with Li Fraumeni syndrome
  • Li-Fraumeni Syndrome

Name

Location